Tag: DK0060606333

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsDK0060606333

LGI Homes Achieves Prestigious Cal/OSHA Golden Gate Recognition for Exemplary Safety Performance at Esplanade Community

D2L Inc. Announces Substantial Issuer Bid

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines –...

Tag: DK0060606333

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us